6-Nov-2025 6:00 AM CST - Business Wire Xeris Biopharma Posts Record Financial Results for the Third Quarter 2025 Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the third quarter ended September 30, 2025. We delivered another record-breaking quarter, driven by increased patient demand across all three products, said John Shannon, Chief Executive Officer. Total product revenue grew 4
23-Oct-2025 6:30 AM CST - Business Wire Xeris Biopharma to Report Third Quarter 2025 Financial Results on November 6, 2025 Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its third quarter 2025 financial results before the open of the U.S. financial markets on Thursday, November 6, 2025. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the
7-Aug-2025 6:00 AM CST - Business Wire Xeris Biopharma Reports Record Financial Results for the Second Quarter 2025 and Raises Full Year Revenue Guidance Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the second quarter ended June 30, 2025, and updated its fiscal 2025 guidance. Total revenue in the second quarter increased almost 50% year-over-year to a record $72 million, driven by increased patient demand across all three
31-Jul-2025 6:30 AM CST - Business Wire Xeris Biopharma to Report Second Quarter 2025 Financial Results on August 7, 2025 Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its second quarter 2025 financial results before the open of the U.S. financial markets on Thursday, August 7, 2025. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the C
3-Jun-2025 6:30 AM CST - Business Wire Xeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor Day Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, will host its first-ever Analyst and Investor Day today to showcase its strategy for sustainable growth and value creation. We have built a strong foundation through innovation and a relentless commitment to improving patient lives. We will showcase how these achi
8-May-2025 6:00 AM CST - Business Wire Xeris Biopharma Reports Record First Quarter 2025 Financial Results Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the first quarter ended March 31, 2025, and updated its fiscal 2025 total revenue guidance. Were very pleased with our strong start to the year, delivering another quarter of outstanding revenue growth, said John Shannon, Xe
6-Mar-2025 6:00 AM CST - Business Wire Xeris Biopharma Delivers Record Fourth Quarter and Full-Year 2024 Results; and Announces 2025 Guidance #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the fourth quarter and full-year ended December 31, 2024 and provides full-year 2025 financial guidance. The Xeris team executed an exceptional 2024 with record revenue topping $203 million, said John Shannon, Xeris Chief Ex
27-Feb-2025 6:00 AM CST - Business Wire Xeris Biopharma to Report Fourth Quarter and Full-Year 2024 Financial Results on March 6, 2025 #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its fourth quarter and full-year 2024 financial results and provide 2025 financial guidance before the open of the U.S. financial markets on Thursday, March 6, 2025. Management will host a conference call and webca
5-Feb-2025 7:00 AM CST - Business Wire Xeris to Participate in Upcoming Investor Conferences #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients lives by developing and commercializing innovative products across a range of therapies, today announced that members of its senior management will take part in the following events: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 1x1 meetings and fireside chat February 12, 2025 at 1:20 pm ET Leerink Global Healthcare Confere
6-Nov-2025 6:00 AM CST - Business Wire Xeris Biopharma Posts Record Financial Results for the Third Quarter 2025 Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the third quarter ended September 30, 2025. We delivered another record-breaking quarter, driven by increased patient demand across all three products, said John Shannon, Chief Executive Officer. Total product revenue grew 4
23-Oct-2025 6:30 AM CST - Business Wire Xeris Biopharma to Report Third Quarter 2025 Financial Results on November 6, 2025 Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its third quarter 2025 financial results before the open of the U.S. financial markets on Thursday, November 6, 2025. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the
7-Aug-2025 6:00 AM CST - Business Wire Xeris Biopharma Reports Record Financial Results for the Second Quarter 2025 and Raises Full Year Revenue Guidance Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the second quarter ended June 30, 2025, and updated its fiscal 2025 guidance. Total revenue in the second quarter increased almost 50% year-over-year to a record $72 million, driven by increased patient demand across all three
31-Jul-2025 6:30 AM CST - Business Wire Xeris Biopharma to Report Second Quarter 2025 Financial Results on August 7, 2025 Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its second quarter 2025 financial results before the open of the U.S. financial markets on Thursday, August 7, 2025. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the C
3-Jun-2025 6:30 AM CST - Business Wire Xeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor Day Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, will host its first-ever Analyst and Investor Day today to showcase its strategy for sustainable growth and value creation. We have built a strong foundation through innovation and a relentless commitment to improving patient lives. We will showcase how these achi
8-May-2025 6:00 AM CST - Business Wire Xeris Biopharma Reports Record First Quarter 2025 Financial Results Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the first quarter ended March 31, 2025, and updated its fiscal 2025 total revenue guidance. Were very pleased with our strong start to the year, delivering another quarter of outstanding revenue growth, said John Shannon, Xe
6-Mar-2025 6:00 AM CST - Business Wire Xeris Biopharma Delivers Record Fourth Quarter and Full-Year 2024 Results; and Announces 2025 Guidance #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the fourth quarter and full-year ended December 31, 2024 and provides full-year 2025 financial guidance. The Xeris team executed an exceptional 2024 with record revenue topping $203 million, said John Shannon, Xeris Chief Ex
27-Feb-2025 6:00 AM CST - Business Wire Xeris Biopharma to Report Fourth Quarter and Full-Year 2024 Financial Results on March 6, 2025 #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its fourth quarter and full-year 2024 financial results and provide 2025 financial guidance before the open of the U.S. financial markets on Thursday, March 6, 2025. Management will host a conference call and webca
5-Feb-2025 7:00 AM CST - Business Wire Xeris to Participate in Upcoming Investor Conferences #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients lives by developing and commercializing innovative products across a range of therapies, today announced that members of its senior management will take part in the following events: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 1x1 meetings and fireside chat February 12, 2025 at 1:20 pm ET Leerink Global Healthcare Confere
